Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium Y 90 monoclonal antibody Hu3S193
- Development stage
- Phase 1
- Lead developer
- Ludwig Cancer Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
**Yttrium Y 90 monoclonal antibody Hu3S193** is an investigational Lewis Y-targeted radioimmunotherapeutic consisting of the humanized IgG1 monoclonal antibody hu3S193 chelated to the beta-emitting radionuclide yttrium-90. It binds the tumor-associated Lewis Y carbohydrate antigen on epithelial malignancies and selectively deposits cytotoxic beta radiation in antigen-expressing tumors and adjacent cells, causing radiation-mediated cellular injury. The agent was developed by Ludwig Cancer Research and evaluated in a completed phase 1 intraperitoneal dose-escalation study in advanced ovarian epithelial cancer; it also showed antitumor activity in Lewis Y-positive breast-cancer xenograft studies. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/yttrium-y-90-monoclonal-antibody-hu3s193))
- Other names
- 90Y-hu3S193Y90 MOAB Hu3S193Y-90 MOAB Hu3S193Y 90 MOAB Hu3S193
02
Targets
LeY (Lewis Y antigen)
Beyond the preview
Go deeper on yttrium Y 90 monoclonal antibody Hu3S193.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium Y 90 monoclonal antibody Hu3S193.